Omeros Corporation OMER today announced that it has obtained an exclusive license from The Regents of the University of California to a new series of antifibrinolytic agents.
These optimized agents represent a significant potential advance in the control of surgical and traumatic bleeding.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
